Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 17/20 | 0.64 |
| ▸ | FAP | Q12884 | 9/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.60 |
| ▸ | POU2F2 | P09086 | 1/20 | 0.60 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.60 |
| ▸ | POU2F1 | P14859 | 1/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.60 |
| ▸ | HRH2 | P25021 | 1/20 | 0.60 |
| ▸ | MC4R | P32245 | 1/20 | 0.60 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.60 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.60 |
| ▸ | GHSR | Q92847 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20296912 | 1.00 | DPP4 (0.64) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL17036591 | 0.86 | DPP4 (0.72) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL3919837 | 0.84 | DPP4 (0.70) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL18344002 | 0.84 | DPP4 (0.70) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL18343936 | 0.84 | DPP4 (0.70) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL12862005 | 0.84 | DPP4 (0.70) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL29350672 | 0.84 | DPP4 (0.70) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL16416909 | 0.83 | DPP4 (0.68) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL15083818 | 0.80 | DPP4 (0.85) | DPP4FAPCHRM1POU2F2ADORA3 | |
| SCHEMBL4479213 | 0.80 | DPP4 (0.62) | DPP4FAPCHRM1POU2F2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111574463-B | Rivastigmine intermediate compound IV | 鲁南制药集团股份有限公司 | 2023-07-14 | — | — | CN | claimed |
| CN-111574520-B | Riagliptin intermediate compound V | 鲁南制药集团股份有限公司 | 2022-08-26 | — | — | CN | claimed |
| CN-114235972-B | Method for determining content of linagliptin impurity RBP-1 | 乳源东阳光药业有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-111574463-B | Rivastigmine intermediate compound IV | 鲁南制药集团股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-4103157-A1 | PHARMACEUTICAL COMPOSITION COMPRISING LINAGLIPTIN AND METFORMIN | Zaklady Farmaceutyczne Polpharma S.A. (PL) | 2022-12-21 | — | — | EP | disclosed |
| CN-111574520-B | Riagliptin intermediate compound V | 鲁南制药集团股份有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-109705121-B | Preparation method of linagliptin intermediate | 深圳市第二人民医院 | 2022-04-01 | — | — | CN | disclosed |
| CN-114235972-A | Method for determining linagliptin impurity RBP-1 content | 乳源东阳光药业有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-109761983-B | Preparation method of linagliptin | 深圳市第二人民医院 | 2022-03-04 | — | — | CN | disclosed |